ទំព័រដើម › មហារីកតំបក់ › តេនណេស៊ី › Nashville
ការសាកល្បងគ្លីនិកសម្រាប់ មហារីកតំបក់ នៅក្នុង Nashville, TN
ការសិក្សាចំនួន 39 សម្រាប់ មហារីកតំបក់ កំពុងរកអ្នកចូលរួមនៅតាមទីតាំងក្នុង និងជុំវិញ Nashville (ក្នុងចម្ងាយប្រហែល 30 ម៉ាយ)។ បើកការសិក្សាមួយដើម្បីមើលថាតើនរណាអាចចូលរួម និងរបៀបទំនាក់ទំនងទៅកាន់ក្រុមការងារសិក្សា។
អត្ថបទសិក្សាផ្លូវការ (អង់គ្លេស)
កំពុងរកអ្នកចូលរួមសម្រាប់ការសិក្សាមួយនៅទីនេះ? លេចធ្លោនៅផ្នែកខាងលើនៃទំព័រនេះ — $99 សម្រាប់ 30 ថ្ងៃ →
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
កំពុងជ្រើសរើសដំណាក់កាល 3
- Sarah Cannon Research Institute, Nashville
- Tennessee Oncology, Nashville
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Sarah Cannon Research Institute, Nashville
- Tennessee Oncology PLLC, Nashville
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
កំពុងជ្រើសរើសដំណាក់កាល 2
- SCRI Oncology Partners, Nashville
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 2
- SCRI Oncology Partners, Nashville
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
A Study of PHN-012 in Patients With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- PHN-012-001 Site, Nashville
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Sarah Cannon Research Institute, Nashville
DESTINY-PANTUMOUR04
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Research Site, Nashville
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Vanderbilt University Medical Center, Nashville
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
កំពុងជ្រើសរើសដំណាក់កាល 2/3
- Henry-Joyce Cancer Clinic, Nashville
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
កំពុងជ្រើសរើសដំណាក់កាល 3
- SCRI Oncology Partners, Nashville
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
កំពុងជ្រើសរើសដំណាក់កាល 3
- Investigative Site US039, Nashville
- Investigative Site US060, Nashville
- Investigative Site US070, Nashville
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- SCRI Oncology Partners, Nashville
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Sarah Cannon Research Institue, Nashville
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Tennessee Oncology, PLLC, Nashville
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Sarah Cannon Research Center, Nashville
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Vanderbilt University/Ingram Cancer Center, Nashville
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
កំពុងជ្រើសរើសដំណាក់កាល 2
- Sarah Cannon Research Institute, Nashville
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
កំពុងជ្រើសរើសដំណាក់កាល 1
- Vanderbilt - Ingram Cancer Center, Nashville
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Sarah Cannon Research Institute, Nashville
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Investigative Site #102, Nashville
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
កំពុងជ្រើសរើសដំណាក់កាល 2
- Vanderbilt-Ingram Cancer Center, Nashville
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
កំពុងជ្រើសរើសដំណាក់កាល 2
- SCRI Oncology Partners, Nashville
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
កំពុងជ្រើសរើសដំណាក់កាល 1
- Sarah Cannon, SCRI Oncology Partners, Nashville
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Vanderbilt University Medical Center, Nashville
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
កំពុងជ្រើសរើសដំណាក់កាល 1
- Research Site, Nashville
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Sarah Cannon Research Institute, Nashville
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Sarah Cannon Research Institute, Nashville
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Sarah Cannon Research Institute, Nashville
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- SCRI Oncology Partners, Nashville
Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Veterans Affairs Medical Center - Nashville, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
Disposable Perfusion Phantom for Accurate DCE (Dynamic Contrast Enhanced)-MRI Measurement of Pancreatic Cancer Therapy Response
កំពុងជ្រើសរើស
- Vanderbilt University Medical Center, Nashville
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
កំពុងជ្រើសរើសដំណាក់កាល 2
- Ohio State University-Telemedicine, Nashville
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
កំពុងជ្រើសរើសការសិក្សាសង្កេតស្វាគមន៍អ្នកស្ម័គ្រចិត្តដែលមានសុខភាពល្អ
- Vanderbilt-Ingram Cancer Center, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Massive Bio SYNERGY-AI site, Nashville
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Tennessee Oncology, Nashville
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Exelixis Clinical Site #6, Nashville
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Vanderbilt University Medical Center, Nashville
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- SCRI Oncology Partners, Nashville
ការសាកល្បងសម្រាប់ មហារីកតំបក់ នៅក្នុងទីក្រុងផ្សេងទៀត
- Houston, TXការសិក្សា 61
- New York City, NYការសិក្សា 60
- Boston, MAការសិក្សា 43
- Los Angeles, CAការសិក្សា 35
- St. Louis, MOការសិក្សា 33
- Arlington, VAការសិក្សា 33
- Baltimore, MDការសិក្សា 31
- San Antonio, TXការសិក្សា 31
- Philadelphia, PAការសិក្សា 26
- Tampa, FLការសិក្សា 26
- Durham, NCការសិក្សា 24
- San Diego, CAការសិក្សា 24
ការសិក្សាផ្សេងទៀតនៅក្នុង Nashville
- Non-Small Cell Lung Cancerការសិក្សា 97
- មហារីកទ្រូងការសិក្សា 81
- មហារីកដែលរីករាលដាលការសិក្សា 70
- មហារីកពោះវៀនធំ និងទ្វារមាសការសិក្សា 69
- មហារីក (គ្រប់ប្រភេទ)ការសិក្សា 65
- មហារីកស៊ុតការសិក្សា 49
- មហារីកតូចការសិក្សា 43
- មហារីកសួតការសិក្សា 40
- មហារីកកោសិកាស្រអាប់នៅក្បាល និងបំបៅកការសិក្សា 39
- មហារីកស្រទាប់ស្បែកស្តីការសិក្សា 38
- មេឡាណូម៉ាការសិក្សា 33
- ជំងឺ Multiple Myelomaការសិក្សា 32
ពី ClinicalTrials.gov, ទិន្នន័យទទួលបាននៅថ្ងៃ 6 តុលា 2026។ ការសិក្នានីមួយៗកំណត់លក្ខខណ្ឌលក្ខណៈសម្បត្តិរបស់ខ្លួន; ក្រុមការងារសិក្សាកំណត់ថាតើនរណាអាចចូលរួម។